Drug intelligence / Profile preview

NVSI-06-08

Development stage: Phase 2
Lead developer: National Vaccine & Serum Institute
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

NVSI-06-08 is a recombinant protein subunit COVID-19 vaccine developed by the National Vaccine & Serum Institute (NVSI), a subsidiary of China National Biotec Group (CNBG) under Sinopharm. It is designed as a broad-spectrum vaccine that integrates antigens from multiple SARS-CoV-2 variants—including the original strain, Beta (K417N/E484K/N501Y), and Kappa (L452R/E484K)—into a single trimeric receptor-binding domain (RBD) immunogen. The vaccine aims to provide enhanced cross-neutralizing immunity against various variants of concern. Clinical studies have shown that when used as a heterologous booster following two doses of BBIBP-CorV, NVSI-06-08 elicits strong neutralizing antibody responses and has an acceptable safety profile[1][3][5]. It has received emergency use authorization in the United Arab Emirates[7].

Brand names: NVSI-06-08NVSI06-08NVSI 06-08
Other names: Sinopharm NVSI COVID-19 vaccinemutI-tri-RBD

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on NVSI-06-08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVSI-06-08.

Explore the full profile